2007 DEA Policy 
NORML
APRIL 8, 2020
As a result, the DEA has been encouraged for over a decade to expand the pool of federally licensed cannabis producers — a move that the agency has largely resisted. In 2016, the agency appeared to reconsider its longstanding policy, and publicly stated for the first time that it would consider additional applicants.
NORML
MARCH 1, 2019
In August 2016, the US Drug Enforcement Administration announced in the US Federal Register that the agency was “adopting a new policy that is designed to increase the number of entities registered under the Controlled Substances Act to grow (manufacture) marijuana to supply legitimate researchers in the United States.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NORML
JANUARY 17, 2019
As the result of a lawsuit, DEA Administrative Law Judge Mary Ellen Bittner in 2007 ruled that expanding the pool of federally licensed providers would be “in the public interest.” The agency ultimately rejected her decision.
Cannabis Law Report
FEBRUARY 10, 2022
Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.
Meadow
JULY 13, 2018
Isa Perez (Head of Business Development at Meadow) moderates the Update from Local Regulators Panel with Joe Devlin (Sacramento Cannabis Policy and Enforcement), Cat Packer (Los Angeles Department of Cannabis Regulation), and Nicole Elliot ( San Francisco Office of Cannabis). Photo Credit: Kandid Kush.
Cannabis Law Report
APRIL 8, 2022
Later that year, Doblin sued the DEA for the first time. MAPS hired Sylvia Thyssen as our first employee , celebrated the 50th anniversary of LSD , outlined perspectives on drug policy , and worked toward facilitating a pilot study for medical marijuana. Lyle Craker, Ph.D.,
Cannabis Law Report
MARCH 25, 2019
Both paths are complex processes in which scientific, medical, policy and political forces have influence. There are other avenues Congress can take besides rescheduling marijuana to ameliorate the seeming breakdown in federalism brought about by federal marijuana policy. It was not a policy priority of the Obama administration.
Expert insights. Personalized for you.
347 
Let's personalize your content